story of the week
Neratinib and Capecitabine for Patients With HER2+ Breast Cancer and Brain Metastases
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases
J. Clin. Oncol 2019 Mar 12;[EPub Ahead of Print], RA Freedman, RS Gelman, CK Anders, ME Melisko, HA Parsons, AM Cropp, K Silvestri, CM Cotter, KP Componeschi, JM Marte, RM Connolly, B Moy, CH Van Poznak, KL Blackwell, SL Puhalla, RC Jankowitz, KL Smith, N Ibrahim, TJ Moynihan, CC O'Sullivan, J Nangia, P Niravath, N Tung, PR Pohlmann, R Burns, MF Rimawi, IE Krop, AC Wolff, EP Winer, NU LinFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.